Table Of Content
Contents
- Executive Summary
- Global Next-Generation Antibody Therapeutics Market
- Product Overview
- Market Definition
- Segmentation
- Assumptions and Acronyms
- Research Methodology
- Research Objectives
- Primary Research
- Secondary Research
- Forecast Model
- Market Size Estimation
- Average Pricing Analysis
- Macro-Economic Indicators
- Market Dynamics
- Growth Drivers
- Restraints
- Opportunity
- Trends
- Correlation & Regression Analysis
- Correlation Matrix
- Regression Matrix
- Recent Development, Policies & Regulatory Landscape
- Risk Analysis
- Demand Risk Analysis
- Supply Risk Analysis
- Global Next-Generation Antibody Therapeutics Market Analysis
- Porters Five Forces
- Threat of New Entrants
- Bargaining Power of Suppliers
- Threat of Substitutes
- Rivalry
- PEST Analysis
- Political
- Economic
- Social
- Technological
- Global Next-Generation Antibody Therapeutics Market
- Market Size & forecast, 2019A-2030F
- By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- By Volume (Million Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Global Next-Generation Antibody Therapeutics Market: Market Segmentation
- By Regions
- North America: (U.S. and Canada) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Latin America: (Brazil, Mexico, Argentina, Rest of Latin America) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa) By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3. By Technology: Market Share (2020-2030F)
12.3.1. Antibody-Drug Conjugates (ADCs), By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3.2. Bispecific Antibodies, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3.3. Antibody Fragments and Antibody-like Proteins, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3.4. Fc-engineered Antibodies, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3.5. Biosimilar Antibody Products, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
- Company Profile
- Hoffmann-La Roche Ltd.
- Company Overview
- Company Total Revenue (Financials)
- Market Potential
- Global Presence
- Key Performance Indicators
- SWOT Analysis
- Product Launch
- Kyowa Hakko Kirin Co. Ltd.
- Seattle Genetics Inc.
- ImmunoGen Inc.
- Bristol-Myers Squibb Company
- Pfizer Inc.
- Amgen Inc
- Biogen
- Xencor Inc
- Other Prominent Players
- Consultant Recommendation
**The above-given segmentation and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
Select License Type
.png){kind=icon}
